Zeolite for Health & Longevity - Quick Reference Sheet

Zeolite for Health & Longevity

Created on 09/12/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A mined volcanic mineral powder that works only in the digestive tract and is not absorbed. Its strongest finding is that it sharply reduces how much ingested lead enters the bloodstream. Almost every human study came from companies selling it. Binding is not selective, so useful minerals leave too. Cheap and low-burden for adults willing to test and monitor. (Full Review)

Protocol

Standard oral dose
~3 g daily
Trials used 1.85–9 g daily of micronised clinoptilolite; practitioners typically settle near 3 g daily
Split rather than single dosing
2–3 doses daily
Splitting maintains binding capacity across the day and reduces the particulate load per dose
Best time of day
Mid-morning and mid-afternoon
Away from meals and medication, on an empty stomach; stomach acid drives the ion exchange
Time to effect
Binding of a co-ingested dose
Immediate
Within the same meal
Symptom-level changes
4–8 weeks
Bowel and lipid studies
Bone and metal-profile changes
Months to years
Osteoporosis and metal-monitoring data

Benefits

Contraindications
  • Solid-organ transplant recipients or anyone on immunosuppressive therapy
  • Chronic kidney disease at eGFR below 30 mL/min/1.73 m² (stage 4–5)
  • Pregnancy and lactation
  • Active inflammatory bowel disease flare, bowel obstruction or stricture
  • Diagnosed Wilson disease or untreated hereditary haemochromatosis
  • Anyone taking a narrow therapeutic index medication who cannot reliably maintain four-hour dose separation
Key Interactions
  • Narrow therapeutic index drugs: levothyroxine, warfarin, digoxin, lithium
  • Antibiotics and anti-seizure medication: tetracyclines, fluoroquinolones (doxycycline, ciprofloxacin), phenobarbital
  • Over-the-counter medications: aspirin, ibuprofen, theophylline, acid-suppressing agents (omeprazole, famotidine)
  • Mineral supplements: iron, zinc, calcium, magnesium, copper, selenium
  • Other binders: activated charcoal, bentonite clay, chlorella, modified citrus pectin, bile-acid binders (cholestyramine, colesevelam)
  • Chelation therapy: succimer, DMPS, calcium-disodium EDTA (specialist supervision)

Risk & Side Effects

  • Medium: Depletion of essential minerals; transient increase in circulating lead
  • Low: Gastrointestinal symptoms; contaminant load in commercial powders
  • Speculative: Reduced absorption of co-administered drugs and nutrients; fibrous zeolite contamination; aluminium released by stomach acid

Monitoring

Marker Target Why
Blood lead Below 1.0 µg/dL Principal target of binding and principal safety signal
Whole blood cadmium, arsenic, mercury Below laboratory detection limit Establishes whether a binding target exists at all
Serum copper 80–120 µg/dL Most consistently depleted essential mineral in long-term use
Serum zinc 90–120 µg/dL Competes for the same exchange sites as toxic cations
Serum sodium 138–142 mmol/L Dropped below reference during long-term supplementation
Serum calcium, albumin-corrected 9.2–10.0 mg/dL Dropped below reference in the osteoporosis cohort
Ferritin 50–150 ng/mL Detects iron depletion from non-selective binding
Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Clearance of mobilised metals and aluminium depends on it
ALT and AST Below 25 U/L (men), below 20 U/L (women) Screens for liver injury attributed to supplements
Complete blood count Haemoglobin 13.5–15.0 g/dL (women), 14.5–16.0 g/dL (men); white cells 4.0–7.0 ×10⁹/L; platelets 175–250 ×10⁹/L Detects anaemia from mineral depletion and the immune-cell shifts reported in one study
Fasting lipid panel Low-density lipoprotein cholesterol below 100 mg/dL, triglycerides below 100 mg/dL The one quantified efficacy signal outside metal binding
Stool zonulin No established target; track change from the individual's own baseline The marker that moved in the endurance trial

Cadence: Mineral and metals panel at baseline, three months and twelve months, then every six to twelve months during continued use; lipids rechecked at eight weeks where that is the target

Qualitative Assessment

  • Stool frequency and consistency, scored on a standard stool form scale
  • Abdominal pain and bloating days per week
  • Constipation, the usual reason for stopping any insoluble binder
  • Energy levels and exercise tolerance, which detect developing iron or mineral depletion before laboratory values fall below range
  • Cognitive clarity and mood